Vigabatrin in refractory complex partial seizures

The evidence of its therapeutic value

Research output: Contribution to journalReview article

Abstract

Vigabatrin (Sabril®) has recently been granted approval in the Unites States for the adjunctive treatment of complex-partial seizures in adults. The drug was first evaluated as a potential therapy for this population decades ago, and it has been available in other parts of the world for some time. Well controlled studies demonstrate that at doses up to 3 g/day, the drug is efficacious as add-on therapy for treatment resistant seizures. However, vigabatrin has been associated with significant side-effects limiting its use, and relegating it to a late therapeutic alternative. Specifically, vigabatrin has been implicated in the development of irreversible peripheral vision loss in a significant number of patients. For this reason, the approval of the drug in the United States was contingent upon the introduction of a rigorous monitoring protocol that must accompany its use. Additionally, the drug has been associated with a relatively high incidence of psychiatric disturbances, although there is disagreement about a direct correlation of these symptoms to the drug. Still, the drug remains a viable alternative for patients who have failed therapy with traditional anti-seizure medications.

Original languageEnglish
Pages (from-to)849-856
Number of pages8
JournalClinical Medicine Insights: Therapeutics
Volume2
DOIs
StatePublished - 2010

Fingerprint

Vigabatrin
Seizures
Pharmaceutical Preparations
Therapeutics
Drug Approval
Psychiatry
Incidence
Population

All Science Journal Classification (ASJC) codes

  • Medicine(all)
  • Pharmaceutical Science
  • Pharmacology

Cite this

@article{11b9302fba0a411a9609a0ab4bcc7d34,
title = "Vigabatrin in refractory complex partial seizures: The evidence of its therapeutic value",
abstract = "Vigabatrin (Sabril{\circledR}) has recently been granted approval in the Unites States for the adjunctive treatment of complex-partial seizures in adults. The drug was first evaluated as a potential therapy for this population decades ago, and it has been available in other parts of the world for some time. Well controlled studies demonstrate that at doses up to 3 g/day, the drug is efficacious as add-on therapy for treatment resistant seizures. However, vigabatrin has been associated with significant side-effects limiting its use, and relegating it to a late therapeutic alternative. Specifically, vigabatrin has been implicated in the development of irreversible peripheral vision loss in a significant number of patients. For this reason, the approval of the drug in the United States was contingent upon the introduction of a rigorous monitoring protocol that must accompany its use. Additionally, the drug has been associated with a relatively high incidence of psychiatric disturbances, although there is disagreement about a direct correlation of these symptoms to the drug. Still, the drug remains a viable alternative for patients who have failed therapy with traditional anti-seizure medications.",
author = "Faulkner, {Michele A.} and Justin Tolman",
year = "2010",
doi = "10.4137/CMT.S3788",
language = "English",
volume = "2",
pages = "849--856",
journal = "Clinical Medicine Insights: Therapeutics",
issn = "1179-559X",
publisher = "Libertas Academica Ltd.",

}

TY - JOUR

T1 - Vigabatrin in refractory complex partial seizures

T2 - The evidence of its therapeutic value

AU - Faulkner, Michele A.

AU - Tolman, Justin

PY - 2010

Y1 - 2010

N2 - Vigabatrin (Sabril®) has recently been granted approval in the Unites States for the adjunctive treatment of complex-partial seizures in adults. The drug was first evaluated as a potential therapy for this population decades ago, and it has been available in other parts of the world for some time. Well controlled studies demonstrate that at doses up to 3 g/day, the drug is efficacious as add-on therapy for treatment resistant seizures. However, vigabatrin has been associated with significant side-effects limiting its use, and relegating it to a late therapeutic alternative. Specifically, vigabatrin has been implicated in the development of irreversible peripheral vision loss in a significant number of patients. For this reason, the approval of the drug in the United States was contingent upon the introduction of a rigorous monitoring protocol that must accompany its use. Additionally, the drug has been associated with a relatively high incidence of psychiatric disturbances, although there is disagreement about a direct correlation of these symptoms to the drug. Still, the drug remains a viable alternative for patients who have failed therapy with traditional anti-seizure medications.

AB - Vigabatrin (Sabril®) has recently been granted approval in the Unites States for the adjunctive treatment of complex-partial seizures in adults. The drug was first evaluated as a potential therapy for this population decades ago, and it has been available in other parts of the world for some time. Well controlled studies demonstrate that at doses up to 3 g/day, the drug is efficacious as add-on therapy for treatment resistant seizures. However, vigabatrin has been associated with significant side-effects limiting its use, and relegating it to a late therapeutic alternative. Specifically, vigabatrin has been implicated in the development of irreversible peripheral vision loss in a significant number of patients. For this reason, the approval of the drug in the United States was contingent upon the introduction of a rigorous monitoring protocol that must accompany its use. Additionally, the drug has been associated with a relatively high incidence of psychiatric disturbances, although there is disagreement about a direct correlation of these symptoms to the drug. Still, the drug remains a viable alternative for patients who have failed therapy with traditional anti-seizure medications.

UR - http://www.scopus.com/inward/record.url?scp=78650720092&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650720092&partnerID=8YFLogxK

U2 - 10.4137/CMT.S3788

DO - 10.4137/CMT.S3788

M3 - Review article

VL - 2

SP - 849

EP - 856

JO - Clinical Medicine Insights: Therapeutics

JF - Clinical Medicine Insights: Therapeutics

SN - 1179-559X

ER -